These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34011035)

  • 1. Bailing Capsule combined with α-ketoacid tablets for stage 3 chronic kidney disease: Protocol of a double-blinded, randomized, controlled trial.
    Hu X; Wang J; Yang H; Ji S; Li Y; Xu B; Cui H
    Medicine (Baltimore); 2021 May; 100(20):e25759. PubMed ID: 34011035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III-IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial.
    Gan J; Wu Y; Gong X; Ma Y; Yu S; Gao J
    Trials; 2019 Aug; 20(1):481. PubMed ID: 31391092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compound α-keto acid tablet supplementation alleviates chronic kidney disease progression via inhibition of the NF-kB and MAPK pathways.
    Wang M; Xu H; Chong Lee Shin OL; Li L; Gao H; Zhao Z; Zhu F; Zhu H; Liang W; Qian K; Zhang C; Zeng R; Zhou H; Yao Y
    J Transl Med; 2019 Apr; 17(1):122. PubMed ID: 30975176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
    Li S; Li JP
    Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of Shenyankangfu tablets for primary glomerulonephritis: study protocol for a randomized controlled trial.
    Kou J; Wu J; Yang HT; He YN; Fang JA; Deng YY; Xie YS; Nie LF; Lin HL; Cai GY; Chen XM
    Trials; 2014 Dec; 15():479. PubMed ID: 25480673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Niaoduqing Particles for Delaying Moderate-to-severe Renal Dysfunction: A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study.
    Zheng Y; Cai GY; He LQ; Lin HL; Cheng XH; Wang NS; Jian GH; Liu XS; Liu YN; Ni ZH; Fang JA; Ding HL; Guo W; He YN; Wang LH; Wang YP; Yang HT; Ye ZM; Yu RH; Zhao LJ; Zhou WH; Li WG; Mao HJ; Zhan YL; Hu Z; Yao C; Wei RB; Chen XM
    Chin Med J (Engl); 2017 Oct; 130(20):2402-2409. PubMed ID: 29052559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
    Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
    Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of Fu-Zheng-Qu-Zhuo oral liquid combined with standard integrated therapy in patients with chronic kidney disease (stage 3-4): A randomized placebo-controlled clinical trial.
    Li S; Rao XR; Dai XW; Pei K; Wang L; Huo BM; Wang XJ; Kong LX; Zhang NN; Lian FM
    Medicine (Baltimore); 2017 Jul; 96(28):e7448. PubMed ID: 28700482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficiency of benazepril combined with wind dispelling and dampness removing chinese herbs on stage 3 chronic kidney disease with wind-dampness syndrome: a prospective study].
    Fang YQ; Lu Y; Wang YJ
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Mar; 32(3):311-6. PubMed ID: 22686073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
    Kimura K; Hosoya T; Uchida S; Inaba M; Makino H; Maruyama S; Ito S; Yamamoto T; Tomino Y; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H; Ohtsu H; Ohashi Y;
    Am J Kidney Dis; 2018 Dec; 72(6):798-810. PubMed ID: 30177485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial.
    Bhandari S; Ives N; Brettell EA; Valente M; Cockwell P; Topham PS; Cleland JG; Khwaja A; El Nahas M
    Nephrol Dial Transplant; 2016 Feb; 31(2):255-61. PubMed ID: 26429974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Keluoxin capsule combined with losartan potassium on diabetic kidney disease: study protocol for a randomized double-blind placebo-controlled multicenter clinical trial.
    Wu R; Wei F; Qu L; Bai L; Li J; Li F; Yan W; Wang Q; Wei J
    Trials; 2020 Nov; 21(1):951. PubMed ID: 33228726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial.
    Zhang L; Li P; Xing CY; Zhao JY; He YN; Wang JQ; Wu XF; Liu ZS; Zhang AP; Lin HL; Ding XQ; Yin AP; Yuan FH; Fu P; Hao L; Miao LN; Xie RJ; Wang R; Zhou CH; Guan GJ; Hu Z; Lin S; Chang M; Zhang M; He LQ; Mei CL; Wang L; Chen X
    Am J Kidney Dis; 2014 Jul; 64(1):57-65. PubMed ID: 24631042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sanjin tablets for acute uncomplicated lower urinary tract infection (syndrome of dampness-heat in the lower jiao): protocol for randomized, double-blind, double-dummy, parallel control of positive drug, multicenter clinical trial.
    Lyu J; Xie YM; Gao Z; Shen JW; Deng YY; Xiang ST; Gao WX; Zeng WT; Zhang CH; Yi DH; Wang LX; Wang ZF
    Trials; 2019 Jul; 20(1):446. PubMed ID: 31324199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.
    Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Achinelli F; Guglielmone HA; Ojeda J; Medina F; Farizano Salazar D; Andino G; Ruiz Diaz NE; Kawerin P; Meza E; Dellamea S; Aquino A; Flores V; Martemucci CN; Vernengo MM; Martinez SM; Segovia JE; Aguirre MG
    Trials; 2020 Nov; 21(1):965. PubMed ID: 33234158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
    Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
    Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there a role for ketoacid supplements in the management of CKD?
    Shah AP; Kalantar-Zadeh K; Kopple JD
    Am J Kidney Dis; 2015 May; 65(5):659-73. PubMed ID: 25682182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial for conventional medicine integrated with traditional Chinese medicine (TCM) in the treatment of patients with chronic kidney disease.
    Xi Y; Lu X; Zhu L; Sun X; Jiang Y; He W; Wei M
    Medicine (Baltimore); 2020 May; 99(21):e20234. PubMed ID: 32481298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The key role of Shenyan Kangfu tablets, a Chinese patent medicine for diabetic nephropathy: study protocol for a randomized, double-blind and placebo-controlled clinical trial.
    Wang H; Mu W; Zhai J; Xing D; Miao S; Wang J; Deng Y; Wang N; Chen H; Yang H; He X; Shang H
    Trials; 2013 Jun; 14():165. PubMed ID: 23738508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.